1 Woldu SL, "What is the role of nephrectomy following complete response to checkpoint inhibitors?" 18 : 60-63, 2018
2 Bex A, "Updated European Association of Urology Guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma" 74 : 805-, 2018
3 Jiang T, "Tumor neoantigens : from basic research to clinical applications" 12 : 93-, 2019
4 Saad AM, "Trends in renal‑cell carcinoma incidence and mortality in the United States in the last 2 decades : a SEER‑based study" 17 : 46-, 2019
5 Stoecklein VM, "Trauma equals danger : damage control by the immune system" 92 : 539-551, 2012
6 Choueiri TK, "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy" 185 : 60-66, 2011
7 Graham J, "The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma" 29 : 507-512, 2019
8 Hudes G, "Temsirolimus, interferon alfa, or both for advanced renal‑cell carcinoma" 356 : 2271-, 2007
9 Choueiri TK, "Systemic therapy for metastatic renal‑cell carcinoma" 376 : 354-, 2017
10 De Bruijn RE, "Surgical safety of cytoreductive nephrectomy following sunitinib : results from multicentre, randomised controlled trial of immediate versus deferred nephrectomy(SURTIME)" 7 : 437-440, 2019
1 Woldu SL, "What is the role of nephrectomy following complete response to checkpoint inhibitors?" 18 : 60-63, 2018
2 Bex A, "Updated European Association of Urology Guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma" 74 : 805-, 2018
3 Jiang T, "Tumor neoantigens : from basic research to clinical applications" 12 : 93-, 2019
4 Saad AM, "Trends in renal‑cell carcinoma incidence and mortality in the United States in the last 2 decades : a SEER‑based study" 17 : 46-, 2019
5 Stoecklein VM, "Trauma equals danger : damage control by the immune system" 92 : 539-551, 2012
6 Choueiri TK, "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy" 185 : 60-66, 2011
7 Graham J, "The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma" 29 : 507-512, 2019
8 Hudes G, "Temsirolimus, interferon alfa, or both for advanced renal‑cell carcinoma" 356 : 2271-, 2007
9 Choueiri TK, "Systemic therapy for metastatic renal‑cell carcinoma" 376 : 354-, 2017
10 De Bruijn RE, "Surgical safety of cytoreductive nephrectomy following sunitinib : results from multicentre, randomised controlled trial of immediate versus deferred nephrectomy(SURTIME)" 7 : 437-440, 2019
11 Motzer RJ, "Sunitinib versus interferon alfa in metastatic renal‑cell carcinoma" 356 : 115-, 2007
12 Méjean A, "Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma" 379 : 417-427, 2018
13 Escudier B, "Sorafenib in advanced clear‑cell renal‑cell carcinoma" 356 : 125-, 2007
14 Massari F, "Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic renal cell carcinoma? A systematic review and meta-analysis evaluating cytoreductive nephrectomy in the era of targeted therapy" 13 : 705-, 2018
15 Fujikawa K, "Serum C‑reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma" 162 : 1934-, 1999
16 Guinan P, "Report of 337 patients with renal cell carcinoma emphasizing 110 with stage IV disease and review of the literature" 64 : 295-, 1997
17 Garfield DH, "Regression of metastatic renal cell carcinoma following nephrectomy" 30 : 190-, 1972
18 Marcus SG, "Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy" 150 : 463-, 1993
19 Mickisch GH, "Radical nephrectomy plus interferon–alfa–based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial" 358 : 966-970, 2001
20 Lahn M, "Pro‑inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma" 35 : 70-, 1999
21 Motzer RJ, "Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma" 22 : 454-463, 2004
22 Robertson CN, "Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells" 144 : 614-, 1990
23 Rini BI, "Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma : final results of CALGB 90206" 28 : 2137-2143, 2010
24 Rini BI, "Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma" 380 : 1116-1127, 2019
25 Motzer RJ, "Pazopanib versus sunitinib in metastatic renal-cell carcinoma" 369 : 722-731, 2013
26 Shapiro DD, "Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors" 29 : 513-520, 2019
27 Motzer RJ, "Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma" 27 : 3584-3590, 2009
28 Motzer RJ, "Nivolumab plus ipilimumab versus sunitinib in advanced renalcell carcinoma" 378 : 1277-1290, 2018
29 Mathieu R, "Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features" 33 : 339-, 2015
30 Flanigan RC, "Nephrectomy followed by interferon alfa‑2b compared with interferon alfa‑2b alone for metastatic renal‑cell cancer" 345 : 1655-, 2001
31 Fallick ML, "Nephrectomy before interleukin-2therapy for patients with metastatic renal cell carcinoma" 158 : 1691-1695, 1997
32 Pantuck AJ, "Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma" 345 : 1711-1712, 2001
33 Bex A, "Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability : initial experience with downsizing to reconsider cytoreductive surgery" 27 : 533-, 2009
34 Motzer RJ, "NCCN guidelines insights:kidney cancer, version 2.2020" 17 : 1278-, 2019
35 Finke JH, "Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics" 19 : 353-364, 2013
36 de Riese W, "Metastatic renal cell carcinoma(RCC) : spontaneous regression, longterm survival and late recurrence" 23 : 13-25, 1991
37 Verra N, "Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy" 48 : 527-, 2005
38 Larcher A, "Individualised indications for cytoreductive nephrectomy : which criteria define the optimal candidates?" 4 : 365-378, 2019
39 Singla N, "Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era : an analysis of the National Cancer Database" 38 : 604-, 2020
40 Gore ME, "Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma" 113 : 12-19, 2015
41 Rouprêt M, "European Association of Urology Guidelines on upper urinary tract urothelial carcinoma : 2020 update" 79 : 62-79, 2021
42 Marchioni M, "Development of a novel risk score to select the optimal candidate for cytoreductive nephrectomy among patients with metastatic renal cell carcinoma. Results from a Multiinstitutional Registry (REMARCC)" 4 : 256-263, 2021
43 "Deferred CytoreductiveNephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial (NORDIC-SUN)" ClinicalTrials.gov
44 Franklin JR, "Cytoreductive surgery in the management of metastatic renal cell carcinoma : the UCLA experience" 14 : 230-, 1996
45 Bennett RT, "Cytoreductive surgery for stage IV renal cell carcinoma" 154 : 32-34, 1995
46 Mejean A, "Cytoreductive nephrectomy(CN)in metastatic renal cancer(mRCC) : update on Carmena trial with focus on intermediate IMDC-risk population" 37 (37): 4508-, 2019
47 Heng DY, "Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma : results from the International Metastatic Renal Cell Carcinoma Database Consortium" 66 : 704-710, 2014
48 Flanigan RC, "Cytoreductive nephrectomy in patients with metastatic renal cancer : a combined analysis" 171 : 1071-, 2004
49 Tabakin AL, "Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic"Chosing Wisely"campaign : a narrative review" 9 : 7337-7349, 2020
50 Bex A, "Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib : the SURTIME randomized clinical trial" 5 : 164-170, 2019
51 Konishi S, "Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma : a real-world multicenter analysis" 36 : 6-, 2018
52 "Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer, the PROBE trial (PROBE)" ClinicalTrials.gov
53 Bakos O, "Combining surgery and immunotherapy : turning an immunosuppressive effect into a therapeutic opportunity" 6 : 86-, 2018
54 Culp SH, "Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?" 116 : 3378-3388, 2010
55 Choueiri TK, "Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk(Alliance A031203 CABOSUN randomised trial) : Progressionfree survival by independent review and overall survival update" 94 : 115-125, 2018
56 Motzer RJ, "Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma" 380 : 1103-1115, 2019
57 Warren M, "A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment" 3 : 281-289, 2009